For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine ...

This discovery could influence treatment strategies for chronic myeloid leukemia (CML) and related cancers. The study, ...

Every year, approximately 700 Canadians are diagnosed with chronic myeloid leukemia (CML), a type of blood cancer that starts in the bone marrow. While there is no cure, people with CML today have a ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

The World Health Organization has defined chronic disease as non-communicable diseases enduring for long durations (five-year ...

Of these, chronic myeloid leukemia (CML) is a subtype that primarily affects the bone marrow, which produces blood cells. The Duke-NUS scientists, in collaboration with their partners, including ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...